# US 2026/0218228 A1 · Recombinant adeno-associated virus vector

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218228 A1
- Document ID: US20260218228A1
- Status: Published application
- Kind: A1
- Application number: 19/142,377
- Filed: 2024-02-01
- Published: 2026-07-30
- Earliest claimed: 2023-02-02
- Assignees: Quethera Limited
- Applicants: Quethera Limited
- Inventors: Kenjiro ADACHI; Naoki KOZONO
- Web page: https://patentgrep.com/patent/US20260218228A1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/06: Antiglaucoma agents or miotics
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/48: Nerve growth factor [NGF]
- C07K 14/71: for growth factors; for growth regulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 27/00: Drugs for disorders of the senses
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/60: from viruses
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Some embodiments relate to adeno-associated virus (rAAV) vectors, in particular rAAV vectors comprising a genetic construct harbouring genes encoding tyrosine receptor kinase B and Brain Derived Neurotrophic Factor. The presently disclosed subject matter also extends to a pharmaceutical composition comprising the rAAV vectors, and to the use of such vectors and compositions in gene therapy methods for preventing or treating a range of optic nerve disorders and cochlear disorders, or for promoting nerve regeneration and/or survival. The presently disclosed subject matter also provides methods of producing the rAAV vectors.

## Claims

### Claim 1

A recombinant adeno-associated virus (rAAV) vector comprising a genetic construct comprising, in a 5′ to 3′ orientation:
a cytomegalovirus (CMV) promoter;
a first coding sequence, which encodes tyrosine kinase receptor B (TrkB);
a nucleotide sequence encoding a linker to generate TrkB and mature brain-derived neurotrophic factor (mBDNF) as individual proteins; and
a second coding sequence, which encodes mBDNF,
wherein the CMV promoter is operably linked to the first and second coding sequences.

### Claim 2 (depends on 1)

The rAAV vector according to claim 1, wherein the CMV promoter comprises a nucleotide sequence as set out in SEQ ID No: 1, or a fragment or variant thereof.

### Claim 3 (depends on 1)

The rAAV vector according to claim 1, wherein the first coding sequence encodes naturally occurring TrkB, or a variant having the function thereof.

### Claim 4 (depends on 1)

The rAAV vector according to claim 1, wherein the first coding sequence encodes an amino acid sequence as set out in SEQ ID No: 2, or a fragment or variant thereof, and/or wherein the first coding sequence comprises a nucleotide sequence as set out in SEQ ID No: 3, or a fragment or variant thereof.

### Claim 5 (depends on 1)

The rAAV vector according to claim 1, wherein the second coding sequence encodes naturally occurring mBDNF.

### Claim 6 (depends on 1)

The rAAV vector according to claim 1, wherein the second coding sequence encodes an amino acid sequence as set out in SEQ ID No: 4, or a fragment or variant thereof, and/or wherein the second coding sequence comprises a nucleotide sequence as set out in SEQ ID No: 5, or a fragment or variant thereof.

### Claim 7 (depends on 1)

The rAAV vector according to claim 1, wherein the genetic construct further comprises a nucleotide sequence encoding a signal peptide, optionally wherein the signal peptide is positioned on the 5′ side of the nucleotide sequence encoding mBDNF, and/or wherein the the nucleotide sequence encoding the signal peptide is positioned on the 3′ side of the nucleotide sequence encoding the linker.

### Claim 8 (depends on 7)

The rAAV vector according to claim 7, wherein the nucleotide sequence encoding the signal peptide encodes an amino acid sequence as set out in SEQ ID No: 6 or SEQ ID No: 20, or a fragment or variant thereof, and/or wherein the signal peptide comprises a nucleotide sequence as set out in SEQ ID No: 7 or SEQ ID No: 21, or a fragment or variant thereof.

### Claim 9 (depends on 1)

The rAAV vector according to claim 1, wherein the linker is a P2A peptide.

### Claim 10 (depends on 1)

The rAAV vector according to claim 1, wherein the nucleotide sequence encoding the linker encodes an amino acid sequence as set out in SEQ ID No: 8, or a fragment or variant thereof, and/or wherein the linker comprises a nucleotide sequence as set out in SEQ ID No: 9, or a fragment or variant thereof.

### Claim 11 (depends on 1)

The rAAV vector according to claim 1, wherein the genetic construct further comprises a nucleotide sequence encoding a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), optionally wherein the WPRE comprises a nucleotide sequence as set out in SEQ ID No: 10, or a fragment or variant thereof.

### Claim 12 (depends on 1)

The rAAV vector according to claim 1, wherein the genetic construct further comprises a nucleotide sequence encoding a polyA signal sequence, optionally wherein the polyA signal sequence comprises a nucleotide sequence as set out in SEQ ID No: 11, or a fragment or variant thereof.

### Claim 13 (depends on 1)

The rAAV vector according to claim 1, wherein the rAAV vector comprises a genetic construct comprising, in a 5′ to 3′ direction, a CMV promoter sequence, a first coding sequence encoding TrkB, a nucleotide sequence encoding a P2A linker peptide, a nucleotide sequence encoding a signal peptide, a second coding sequence encoding mBDNF, a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and a simian virus 40 (SV40) polyA signal sequence.

### Claim 14 (depends on 1)

The rAAV vector according to claim 1, wherein the genetic construct comprises a nucleotide sequence as set out in any one of SEQ ID No: 14 to 17, or a variant or fragment thereof.

### Claim 15 (depends on 1)

The rAAV vector according to claim 1, wherein the rAAV vector is a rAAV2 vector.

### Claim 16 (depends on 1)

The rAAV vector according to claim 1, wherein the rAAV vector is a rAAV2.7m8 vector.

### Claim 17 (depends on 1)

The rAAV vector according to claim 1, for use as a medicament or in therapy.

### Claim 18 (depends on 1)

The rAAV vector according to claim 1, for use in treating, preventing or ameliorating an optic nerve disorder and/or a retinal degenerative disease involving retinal ganglion cell degeneration.

### Claim 19 (depends on 18)

The rAAV vector according to claim 18, wherein the optic nerve disorder and/or retinal degenerative disease involving retinal ganglion cell degeneration is glaucoma or glaucoma optic neuropathy.

### Claim 20 (depends on 1)

A method of treating, preventing or ameliorating an optic nerve disorder and/or a retinal degenerative disease involving retinal ganglion cell degeneration in a subject, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of the rAAV vector according to claim 1.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the recombinant rAAV vector according to claim 1, and a pharmaceutically acceptable vehicle.

### Claim 22 (depends on 1, 21)

A method of preparing the pharmaceutical composition according to claim 21, the method comprising contacting the recombinant rAAV vector according to claim 1, with a pharmaceutically acceptable vehicle.

### Claim 23 (depends on 1)

A method for producing the rAAV vector according to claim 1, the method comprising:
(i) introducing, into a rAAV vector-producing cell, a genetic construct comprising, in a 5′ to 3′ orientation:
a cytomegalovirus (CMV) promoter;
a first coding sequence, which encodes tyrosine kinase receptor B (TrkB);
a nucleotide sequence encoding a linker to generate TrkB and mature brain-derived neurotrophic factor (mBDNF) as individual proteins; and
a second coding sequence, which encodes mBDNF,
wherein the CMV promoter is operably linked to the first and second coding sequence; and
(ii) culturing the rAAV vector-producing cell, to thereby produce the rAAV vector according to claim 1.

### Claim 24 (depends on 1)

A rAAV vector-producing cell comprising the genetic construct of the rAAV vector of claim 1.
